News Archive

18 September 2014

Merck Animal Health Continues Long-Standing Commitment to Bovine Veterinary Students’ Education

Summit, N.J., September 18, 2014 – During the past decade, Merck Animal Health has presented 87 outstanding bovine veterinary students with the American Association of Bovine Practitioners (AABP) Bovine Veterinary Student Recognition Award. At the 2014 AABP Annual Conference in Milwaukee, Merck Animal Health recognized another 15 of the industry’s top future leaders in bovine veterinary medicine and awarded each a $5,000 scholarship, as well as an all-expenses-paid trip to attend the conference.

“The contributions that large animal veterinarians make to our world are immeasurable,” said Norman Stewart, D.V.M., livestock technical services manager for Merck Animal Health. “They help keep our animals healthy and our food safe and affordable. We at Merck Animal Health are proud to support and invest in those who are so vital to our future. The service, ideas and insight these students will provide throughout their careers will well exceed the scope of the education and support they receive.”

The following students* are recipients of the 2014 AABP Bovine Veterinary Student Recognition Awards:

  • Chelsea Allan, Ontario Veterinary College at the University of Guelph
  • Benjamin Baird, Washington State University College of Veterinary Medicine
  • Lindsey Borst, University of Minnesota College of Veterinary Medicine
  • Julie Conner, University of California-Davis School of Veterinary Medicine
  • J.D. Folsom, Oklahoma State University College of Veterinary Health Sciences
  • Jacob Hagenmaier, Kansas State University College of Veterinary Medicine
  • Jennifer R. Holle, University of Wisconsin-Madison School of Veterinary Medicine
  • Daniel J. Lopez, Cornell University College of Veterinary Medicine
  • Lee Michels, University of Minnesota College of Veterinary Medicine
  • Halley Oliveira, Cornell University College of Veterinary Medicine
  • Emily K. Severt, Ohio State University College of Veterinary Medicine
  • McKenzie Steger, Iowa State University College of Veterinary Medicine
  • Peter A. Strassburg, University of Wisconsin-Madison School of Veterinary Medicine
  • Holt Tripp, Oklahoma State University Center for Veterinary Health Sciences
  • Ashley Zondlak, Michigan State University College of Veterinary Medicine

Veterinary students in their third or fourth year of college are eligible to receive the award. Recipients of the scholarship are selected based on academic achievement, career goals, work experience and interest in veterinary medicine.

“Meeting with these students, seeing their enthusiasm and watching them make connections that may define their careers, is an honor and privilege I look forward to each year,” said AABP Executive Vice President M. Gatz Riddell, D.V.M. “We thank Merck Animal Health for helping to motivate and recognize the next generation of bovine practitioners.” 

About Merck Animal Health
Today's Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck.Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit or connect with us on LinkedIn and Twitter at @MerckAH.

Merck Forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2013 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (